Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 1/20 | 0.76 |
| ▸ | ACLY | P53396 | 5/20 | 0.53 |
| ▸ | PTGES2 | Q9H7Z7 | 2/20 | 0.51 |
| ▸ | PGR | P06401 | 1/20 | 0.46 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.44 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.44 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.42 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.42 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26844403 | 0.90 | CRBN (0.70) | CRBNACLYPTGES2PGRGLO1 | |
| E-7820 SCHEMBL1581157 | 0.86 | CRBN (1.00) | CRBNACLYPTGES2PGRGLO1 | |
| E-7820 SCHEMBL2950395 | 0.86 | CRBN (1.00) | CRBNACLYPTGES2PGRGLO1 | |
| E-7820 SCHEMBL31237463 | 0.86 | CRBN (1.00) | CRBNACLYPTGES2PGRGLO1 | |
| SCHEMBL21218180 | 0.85 | CRBN (0.78) | CRBNACLYPTGES2PGRGLO1 | |
| SCHEMBL21218179 | 0.85 | CRBN (0.78) | CRBNACLYPTGES2PGRGLO1 | |
| SCHEMBL22428369 | 0.85 | CRBN (0.82) | CRBNACLYPTGES2PGRGLO1 | |
| SCHEMBL21218178 | 0.85 | CRBN (0.78) | CRBNACLYPTGES2PGRGLO1 | |
| SCHEMBL21218177 | 0.82 | CRBN (0.77) | CRBNACLYPTGES2PGRGLO1 | |
| SCHEMBL21218349 | 0.82 | ACLY (0.54) | CRBNACLYPTGES2PGRGLO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11807606-B2 | Sulfonamide derivatives for protein degradation | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11807606-B2 | Sulfonamide derivatives for protein degradation | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20200290964-A1 | SULFONAMIDE DERIVATIVES FOR PROTEIN DEGRADATION | DANA-FARBER CANCER INSTITUTE, INC. | 2020-09-17 | — | — | US | disclosed |
| WO-2019147783-A1 | SULFONAMIDE DERIVATIVES FOR PROTEIN DEGRADATION | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200290964-A1 | SULFONAMIDE DERIVATIVES FOR PROTEIN DEGRADATION | CUL5, CUL4A, DCAF1 | CRBN 14/4885ACLY 2332/4885PTGES2 4806/4885 |
| US-11807606-B2 | Sulfonamide derivatives for protein degradation | CUL5, CUL4A, DCAF1 | CRBN 14/4885ACLY 2332/4885PTGES2 4806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.